NERV News and Press, Minerva Neurosciences Inc

2024-05-01 13:53:20 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Minerva Neurosciences (NASDAQ: NERV ) just reported results for the first quarter of 2024. Minerva Neurosciences reported earnings per share of -$1.13. This was above the ...

2024-05-01 07:35:35 ET More on Minerva Neurosciences Minerva falls as FDA rejects schizophrenia therapy Seeking Alpha’s Quant Rating on Minerva Neurosciences Historical earnings data for Minerva Neurosciences Financial information for Minerva Neuroscie...

BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...

A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...

BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the U.S. Food and Drug Administration (FDA) has i...

2024-02-08 12:23:40 ET Read the full article on Seeking Alpha For further details see: SUNW, NSTG and NERV among mid-day movers

2024-02-05 13:05:53 ET More on Mid-day movers $ stocks. Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade) Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky Peraso Inc. (PRSO) Q3 2023 Earnings Ca...

Minerva Neurosciences Inc (NERV) is expected to report $-0.77 for Q3 2023

2023-11-07 08:20:07 ET More on Minerva Neurosciences Minerva Neurosciences: There's Probably Time For One More Rally Seeking Alpha’s Quant Rating on Minerva Neurosciences Historical earnings data for Minerva Neurosciences Financial information for Mine...

BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the third qu...